J Korean Neurosurg Soc.  2018 May;61(3):376-385. 10.3340/jkns.2018.0057.

Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor

Affiliations
  • 1Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. shparknp@snu.ac.kr jkwon@snuh.org
  • 2Department of Neuroscience Institute, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Recent discoveries of brain tumor-related genes and fast advances in genomic testing technologies have led to the era of molecular diagnosis of brain tumor. Molecular profiling of brain tumor became the significant step in the diagnosis, the prediction of prognosis and the treatment of brain tumor. Because traditional molecular testing methods have limitations in time and cost for multiple gene tests, next-generation sequencing technologies are rapidly introduced into clinical practice. Targeted sequencing panels using these technologies have been developed for brain tumors. In this article, focused on pediatric brain tumor, key discoveries of brain tumor-related genes are reviewed and cancer panels used in the molecular profiling of brain tumor are discussed.

Keyword

Brain neoplasms; Pediatrics; Molecular diagnostics; High-throughput nucleotide sequencing; Next generation sequencing

MeSH Terms

Brain Neoplasms*
Brain*
Diagnosis*
High-Throughput Nucleotide Sequencing
Pathology, Molecular
Pediatrics
Prognosis

Reference

References

1. Araki A, Chocholous M, Gojo J, Dorfer C, Czech T, Heinzl H, et al. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. Acta Neuropathol Commun. 4:88. 2016.
Article
2. Bai RY, Staedtke V, Rudin CM, Bunz F, Riggins GJ. Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro Oncol. 17:545–554. 2015.
Article
3. Bavle AA, Lin FY, Parsons DW. Applications of genomic sequencing in pediatric CNS tumors. Oncology (Williston Park). 30:411–423. 2016.
4. Behling F, Barrantes-Freer A, Skardelly M, Nieser M, Christians A, Stockhammer F, et al. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol. 11:55. 2016.
5. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 456:53–59. 2008.
6. Blumenthal DT, Dvir A, Lossos A, Tzuk-Shina T, Lior T, Limon D, et al. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. J Neurooncol. 130:211–219. 2016.
Article
7. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008.
Article
8. Carter JH, McNulty SN, Cimino PJ, Cottrell CE, Heusel JW, Vigh-Conrad KA, et al. Targeted next-generation sequencing in molecular subtyping of lower-grade diffuse gliomas: application of the World Health Organization’s 2016 revised criteria for Central Nervous System Tumors. J Mol Diagn. 19:328–337. 2017.
Article
9. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 31:737–754.e6. 2017.
10. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 164:550–563. 2016.
11. Cho HJ, Myung JK, Kim H, Park CK, Kim SK, Chung CK, et al. Primary diffuse leptomeningeal glioneuronal tumors. Brain Tumor Pathol. 32:49–55. 2015.
Article
12. Cornejo KM, Cheng L, Church A, Wang M, Jiang Z. Chromosome 12p abnormalities and IMP3 expression in prepubertal pure testicular teratomas. Hum Pathol. 49:54–60. 2016.
Article
13. Dal Cin P, Dei Tos AP, Qi H, Giannini C, Furlanetto A, Longatti PL, et al. Immature teratoma of the pineal gland with isochromosome 12p. Acta Neuropathol. 95:107–110. 1998.
Article
14. de Bruin TW, Slater RM, Defferrari R, Geurts van Kessel A, Suijkerbuijk RF, Jansen G, et al. Isochromosome 12p-positive pineal germ cell tumor. Cancer Res. 54:1542–1544. 1994.
15. Dodgshun AJ, SantaCruz N, Hwang J, Ramkissoon SH, Malkin H, Bergthold G, et al. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 128:293–302. 2016.
Article
16. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, et al. Activating mutations in BRAF characterize a spectrum of pediatric lowgrade gliomas. Neuro Oncol. 12:621–630. 2010.
Article
17. Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Idbaih A, et al. Molecular classification of anaplastic oligodendroglioma using nextgeneration sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol. 18:388–400. 2016.
Article
18. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 121:381–396. 2011.
Article
19. Gajjar A, Pfister SM, Taylor MD, Gilbertson RJ. Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res. 20:5630–5640. 2014.
Article
20. Gardiman MP, Fassan M, Orvieto E, D’Avella D, Denaro L, Calderone M, et al. Diffuse leptomeningeal glioneuronal tumors: a new entity? Brain Pathol. 20:361–366. 2010.
Article
21. Gessi M, Zur Muehlen A, Lauriola L, Gardiman MP, Giangaspero F, Pietsch T. TP53, beta-Catenin and c-myc/N-myc status in embryonal tumours with ependymoblastic rosettes. Neuropathol Appl Neurobiol. 37:406–413. 2011.
Article
22. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 468:1095–1099. 2010.
Article
23. Hasselblatt M, Gesk S, Oyen F, Rossi S, Viscardi E, Giangaspero F, et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol. 35:933–935. 2011.
Article
24. Helfferich J, Nijmeijer R, Brouwer OF, Boon M, Fock A, Hoving EW, et al. Neurofibromatosis type 1 associated low grade gliomas: a comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol. 104:30–41. 2016.
Article
25. Hood L, Rowen L. The Human Genome Project: big science transforms biology and medicine. Genome Med. 5:79. 2013.
Article
26. Hoshide R, Jandial R. 2016 World Health Organization classification of central nervous system tumors: an era of molecular biology. World Neurosurg. 94:561–562. 2016.
Article
27. Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for validation of next-generation sequencing-Based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 19:341–365. 2017.
Article
28. Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist. 22:1478–1490. 2017.
Article
29. Joyon N, Tauziède-Espariat A, Alentorn A, Giry M, Castel D, Capelle L, et al. K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway. Neuropathol Appl Neurobiol. 43:271–276. 2017.
Article
30. Kallappagoudar S, Yadav RK, Lowe BR, Partridge JF. Histone H3 mutations--a special role for H3.3 in tumorigenesis? Chromosoma. 124:177–189. 2015.
Article
31. Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol. 16:1408–1416. 2014.
Article
32. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion : epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 29:2121–2127. 2011.
Article
33. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124:439–447. 2012.
Article
34. Kim J, Park WY, Kim NKD, Jang SJ, Chun SM, Sung CO, et al. Good laboratory standards for clinical next-generation sequencing cancer panel tests. J Pathol Transl Med. 51:191–204. 2017.
Article
35. Kleinman CL, Gerges N, Papillon-Cavanagh S, Sin-Chan P, Pramatarova A, Quang DA, et al. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet. 46:39–44. 2014.
Article
36. Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 19:699–709. 2017.
Article
37. Korshunov A, Sturm D, Ryzhova M, Hovestadt V, Gessi M, Jones DT, et al. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol. 128:279–289. 2014.
Article
38. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131:803–820. 2016.
Article
39. Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handb Clin Neurol. 134:97–120. 2016.
Article
40. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 11:31–46. 2010.
Article
41. Mostert M, Rosenberg C, Stoop H, Schuyer M, Timmer A, Oosterhuis W, et al. Comparative genomic and in situ hybridization of germ cell tumors of the infantile testis. Lab Invest. 80:1055–1064. 2000.
Article
42. Movassaghi M, Shabihkhani M, Hojat SA, Williams RR, Chung LK, Im K, et al. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Exp Mol Pathol. 103:87–93. 2017.
Article
43. Nambirajan A, Malgulwar PB, Sharma MC, Singh A, Pathak P, Satyarthee GD, et al. C11orf95-RELA fusion present in a primary intracranial extraaxial ependymoma: report of a case with literature review. Neuropathology. 36:490–495. 2016.
Article
44. Nikbakht H, Panditharatna E, Mikael LG, Li R, Gayden T, Osmond M, et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun. 7:11185. 2016.
Article
45. Nikiforova MN, Wald AI, Melan MA, Roy S, Zhong S, Hamilton RL, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol. 18:379–387. 2016.
Article
46. Nobusawa S, Hirato J, Yokoo H. Molecular genetics of ependymomas and pediatric diffuse gliomas : a short review. Brain Tumor Pathol. 31:229–233. 2014.
Article
47. Nobusawa S, Orimo K, Horiguchi K, Ikota H, Yokoo H, Hirato J, et al. Embryonal tumor with abundant neuropil and true rosettes with only one structure suggestive of an ependymoblastic rosette. Pathol Int. 64:472–477. 2014.
Article
48. Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 547:311–317. 2017.
Article
49. Okada Y, Nishikawa R, Matsutani M, Louis DN. Hypomethylated X chromosome gain and rare isochromosome 12p in diverse intracranial germ cell tumors. J Neuropathol Exp Neurol. 61:531–538. 2002.
Article
50. Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 27:728–743. 2015.
Article
51. Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature. 506:451–455. 2014.
Article
52. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008.
Article
53. Pietsch T, Haberler C. Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline. Clin Neuropathol. 35:344–352. 2016.
Article
54. Poulos C, Cheng L, Zhang S, Gersell DJ, Ulbright TM. Analysis of ovarian teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for teratomatous elements. Mod Pathol. 19:766–771. 2006.
Article
55. Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 131:833–845. 2016.
Article
56. Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF, Schumacher SE, et al. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 19:986–996. 2017.
Article
57. Rickert CH, Simon R, Bergmann M, Dockhorn-Dworniczak B, Paulus W. Comparative genomic hybridization in pineal germ cell tumors. J Neuropathol Exp Neurol. 59:815–821. 2000.
Article
58. Roth JJ, Santi M, Pollock AN, Harding BN, Rorke-Adams LB, Tooke LS, et al. Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade gliomas. Brain Pathol. 25:182–192. 2015.
Article
59. Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, et al. Nextgeneration sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 131:903–910. 2016.
Article
60. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121:397–405. 2011.
Article
61. Schneider DT, Schuster AE, Fritsch MK, Calaminus G, Harms D, Göbel U, et al. Genetic analysis of childhood germ cell tumors with comparative genomic hybridization. Klin Padiatr. 213:204–211. 2001.
Article
62. Schneider DT, Zahn S, Sievers S, Alemazkour K, Reifenberger G, Wiestler OD, et al. Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Mod Pathol. 19:864–873. 2006.
Article
63. Schulte SL, Waha A, Steiger B, Denkhaus D, Dörner E, Calaminus G, et al. CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways. Oncotarget. 7:55026–55042. 2016.
Article
64. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 482:226–231. 2012.
65. Schweizer Y, Meszaros Z, Jones DTW, Koelsche C, Boudalil M, Fiesel P, et al. Molecular transition of an adult low-grade brain tumor to an atypical teratoid/rhabdoid tumor over a time-course of 14 years. J Neuropathol Exp Neurol. 76:655–664. 2017.
Article
66. Silver SA, Wiley JM, Perlman EJ. DNA ploidy analysis of pediatric germ cell tumors. Mod Pathol. 7:951–956. 1994.
67. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature. 448:561–566. 2007.
Article
68. Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 26:569–580. 2016.
Article
69. Spence T, Perotti C, Sin-Chan P, Picard D, Wu W, Singh A, et al. A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes. Neuro Oncol. 16:62–71. 2014.
Article
70. Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, et al. New brain tumor entities emerge from molecular classification of CNSPNETs. Cell. 164:1060–1072. 2016.
71. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 22:425–437. 2012.
72. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123:465–472. 2012.
Article
73. Tomić TT, Olausson J, Wilzén A, Sabel M, Truvé K, Sjögren H, et al. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. PLoS One. 12:e0175638. 2017.
74. Trabelsi S, Chabchoub I, Ksira I, Karmeni N, Mama N, Kanoun S, et al. Molecular diagnostic and prognostic subtyping of gliomas in tunisian population. Mol Neurobiol. 54:2381–2394. 2017.
Article
75. Wong SQ, Li J, Tan AY, Vedururu R, Pang JM, Do H, et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics. 7:23. 2014.
Article
76. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 44:251–253. 2012.
Article
77. Wu J, Armstrong TS, Gilbert MR. Biology and management of ependymomas. Neuro Oncol. 18:902–913. 2016.
Article
78. Yu IT, Griffin CA, Phillips PC, Strauss LC, Perlman EJ. Numerical sex chromosomal abnormalities in pineal teratomas by cytogenetic analysis and fluorescence in situ hybridization. Lab Invest. 72:419–423. 1995.
79. Zacher A, Kaulich K, Stepanow S, Wolter M, Kohrer K, Felsberg J, et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel. Brain Pathol. 27:146–159. 2017.
Article
80. Zhang C, Berney DM, Hirsch MS, Cheng L, Ulbright TM. Evidence supporting the existence of benign teratomas of the postpubertal testis: a clinical, histopathologic, and molecular genetic analysis of 25 cases. Am J Surg Pathol. 37:827–835. 2013.
Article
81. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, et al. Wholegenome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 45:602–612. 2013.
Article
82. Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 31:2927–2935. 2013.
Article
Full Text Links
  • JKNS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr